FDA advisers back gene therapy for rare form of blindness

    loading  Checking for direct PDF access through Ovid

Abstract

Therapy that targets disease-causing mutations could become the first of its kind approved for use in the United States.

Heidi writes about biology and medicine, and has a PhD from the University of California, Berkeley. Heidi has written for The Oregonian, edited for the Berkeley Science Review, and freelanced for a few other publications.

Related Topics

    loading  Loading Related Articles